Latest News and Press Releases

First publicly listed company to actively investigate psilocybin’s potential impact on longevity NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed”...

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...

COLUMBUS, Ohio, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Over the last decade, increased media attention on the potential benefits of using psychedelic drugs for medicinal and therapeutic purposes has led...

NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Psyence BioMed (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies...

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...

PharmAla files its final short form prospectus, and announces a signed term sheet with an R&D tax credit financing firm called Radium

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and Ibogaine...

Fungushead has announced its new Angel’s Wing Scholarship, providing a lifetime 25% discount for verified U.S. military vets

PharmAla launches new web portal for MDMA prescribers and appoints a new COO

PharmAla completes first domestic US shipment of MDMA from its new domestic distribution center, and issues shares as debt payment.